Adagrasib/Cetuximab Combo Has Activity in KRAS G12C+ Locally

Adagrasib plus cetuximab elicited a 34% objective response rate in patients with previously treated KRAS G12C-mutant advanced colorectal cancer.

Related Keywords

Texas , United States , Houston , San Diego , California , American , Daiichi Sankyo , Bristol Meyers Squibb , Redx Pharma , Eli Lilly , Navire Pharma , Genentech Roche , Scott Kopetz , Astrazeneca Medimmune , Lutris Pharma , Bristol Myers Squibb Medarex , Bayer Health , Drug Administration , Iylon Precision Oncology , Gilead Sciences , University Of Texas Md Anderson Cancer Center , Serono Inc , Takeda Pharmaceuticals , Boehringer Ingelheim , Jazz Pharmaceuticals , Zentalis Pharmaceuticals , Foundation Medicine , Johnson Janssen Pharmaceuticals , Amgen , Novartis , Guardant Health , Jacobio Pharmaceuticals Group Co , Xilis Inc , Pfizer , Harbinger Health , Servier Pharmaceuticals , Genomic Health , Tachyon Therapeutics Inc , Translational Integration , Cancer Center , National Comprehensive Cancer Network , Clinical Practice Guidelines , African American , Frontier Medicines , Holy Stone Healthcare , Jacobio Pharmaceuticals Group , Repare Therapeutics , Mirati Therapeutics , Flame Biosciences , Carina Biotech , Bicara Therapeutics , Endeavor Biomedicines , Numab Therapeutics , Janssen Pharmaceuticals , Taiho Pharmaceutical , Cardiff Oncology , Ono Pharmaceutical , Bristol Myers , Blackstone Therapeutics , Accademia Nazionale , Tachyon Therapeutics , Array Biopharma , Published April , Adagrasib , Cetuximab , Krazati , Erbitux , Adagrasib Plus Cetuximab , Colorectal Cancer , Crc , Kras G12c , Kras G12c Crc , Taacr , Aacr Annual Meeting , Krystal 1 Trial , Cancer Discovery , D , Phd , The University Of Texas Md Anderson Cancer Center ,